ABNB vs ABT Stock Comparison

Scores Breakdown

Metric	ABNB	ABT
📈 Growth	14/30	18/30
💰 Profitability	18/20	17/20
🏦 Financial Health	16/20	18/20
💵 Valuation	13/20	12/20
⚠️ Risk (lower is better)	7/10	4/10
Overall Score	64/100	71/100

Side-by-Side Summaries

ABNB Analysis	ABT Analysis
📈 Growth & Financial Trajectory Over 8 quarters, Revenue declined modestly from $3.732B in Q3 2024 to $3.608B in Q2 2026, while Net Income rose from $461M to $816M, with a peak of $1.374B in Q3 2025 before a mid-year dip. This shows profitability resilience amid revenue variability, driven by episodic operating leverage. Overall, the growth signal is modest on revenue but improving on bottom-line momentum into Q2 2026. 💰 Margins & Cash Flow Gross Margin has remained high, generally in the mid to high 70s up to mid 80s percent across quarters. Operating Margin has been volatile, ranging from near-breakeven to about 39–61% in select quarters, recently around 21% in Q2 2026 as scale expands. Net cash flow from operating activities has been positive in most periods (e.g., ~$1.79B in Q1 2025; $1.27B in Q2 2026), with notable quarterly outflows in Q4 2025 (-$3.73B), reflecting seasonality and financing/investing activity. 🛡️ Balance Sheet & Liquidity Current assets consistently in the low 20s of billions vs current liabilities in the mid to high teens, yielding a healthy current ratio (~1.4–1.6). Long-term debt sits around $2.48B, with equity around $7.6–8.7B across periods, indicating modest leverage and solid equity base. Liabilities plus equity align with asset bases, suggesting liquidity resilience. ⚠️ Key Drivers & Risks Drivers: Travel demand resurgence; network effects and marketplace scale. Risks: Travel cyclicality and regulatory/commercial risk; valuation sensitivity to quarterly volatility and travel headlines.	📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

ABNB Analysis

ABT Analysis

📈 Growth & Financial Trajectory

Over 8 quarters, Revenue declined modestly from $3.732B in Q3 2024 to $3.608B in Q2 2026, while Net Income rose from $461M to $816M, with a peak of $1.374B in Q3 2025 before a mid-year dip. This shows profitability resilience amid revenue variability, driven by episodic operating leverage. Overall, the growth signal is modest on revenue but improving on bottom-line momentum into Q2 2026.

💰 Margins & Cash Flow

Gross Margin has remained high, generally in the mid to high 70s up to mid 80s percent across quarters.
Operating Margin has been volatile, ranging from near-breakeven to about 39–61% in select quarters, recently around 21% in Q2 2026 as scale expands.
Net cash flow from operating activities has been positive in most periods (e.g., ~$1.79B in Q1 2025; $1.27B in Q2 2026), with notable quarterly outflows in Q4 2025 (-$3.73B), reflecting seasonality and financing/investing activity.

🛡️ Balance Sheet & Liquidity

Current assets consistently in the low 20s of billions vs current liabilities in the mid to high teens, yielding a healthy current ratio (~1.4–1.6).
Long-term debt sits around $2.48B, with equity around $7.6–8.7B across periods, indicating modest leverage and solid equity base. Liabilities plus equity align with asset bases, suggesting liquidity resilience.

⚠️ Key Drivers & Risks

Drivers: Travel demand resurgence; network effects and marketplace scale.
Risks: Travel cyclicality and regulatory/commercial risk; valuation sensitivity to quarterly volatility and travel headlines.

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

Similar Companies

AMZN Score: 80 BKNG Score: 69 DASH Score: 76 EXPE Score: 63 GOOG Score: 80 GOOGL Score: 80 KEYS Score: 67 MAR Score: 57 META Score: 76 UBER Score: 72

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"